BioCentury
ARTICLE | Clinical News

GCS-100: Phase IIa started

July 15, 2013 7:00 AM UTC

La Jolla began a single-blind, placebo-controlled, U.S. Phase IIa trial to evaluate 1.5 and 30 mg/m 2 IV GCS-100 once weekly for 8 weeks in about 117 patients with stage 3b and 4 CKD. ...